secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARVARD BIOSCIENCE INC (HBIO)
CIK:        0001123494
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001171843-22-005340
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harvard Bioscience Q2 revenue flat, cuts workforce; guides to 1-5% growth and 13-14% op margin
--------------------------------------------------------------------------------

- Q2 revenue flat at $29.2M; GAAP operating income $4.0M includes $4.9M litigation benefit.
- Adjusted operating income $3.1M vs $4.3M YoY; adjusted EPS $0.05 vs $0.06.
- Gross margin improved to 58% from 57%.
- Company discontinuing non-strategic products and cutting ~5% of global workforce.
- FY2022 guidance: 1-5% reported revenue growth; adjusted operating margin 13-14%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1123494/000117184322005340/0001171843-22-005340-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1123494/000117184322005340/f8k_080422.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-005340

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer